Promoter Chirayu Amin, acting for himself and on behalf of persons acting in concert, has submitted a formal declaration to the stock exchanges confirming that no encumbrance was created, either directly or indirectly, on the shares of Alembic Pharmaceuticals during the financial year 2025-26. The declaration, dated 3rd April, 2026, was filed with both BSE Limited and the National Stock Exchange of India Ltd. in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SAST Regulations").

Regulatory Declaration Under SAST Regulations

The declaration confirms that since no encumbrance was made on the shares of the target company during FY 2025-26, no disclosures were required to be made under the SAST Regulations for the said period. This filing is a standard compliance requirement under SEBI's framework governing substantial acquisition of shares and takeovers, mandating promoters and persons acting in concert to disclose or confirm the status of encumbrances on their shareholding at the close of each financial year.

Promoters and Persons Acting in Concert

The declaration covers a comprehensive list of promoters and promoter group entities. The following individuals and entities are identified as persons acting in concert with Chirayu Amin for the purposes of this declaration:

Key Highlights of the Declaration

• The declaration was submitted to both BSE Limited and the National Stock Exchange of India Ltd.
• No encumbrance was created, directly or indirectly, on shares of Alembic Pharmaceuticals during FY 2025-26.
• As a result, no further disclosures were required under the SAST Regulations for the relevant period.
• The filing covers 34 entities and individuals comprising the promoter and promoter group.

The declaration underscores the promoter group's adherence to SEBI's regulatory disclosure requirements, confirming the unencumbered status of their shareholding in Alembic Pharmaceuticals for the financial year 2025-26.

Alembic Pharmaceuticals has successfully cleared a Good Manufacturing Practice (GMP) inspection conducted by Brazil's National Health Surveillance Agency, Anvisa, at its Karakhadi API-III facility. The inspection encompassed multiple active pharmaceutical ingredients (APIs), all of which were completed without any observations or issues.

Regulatory Milestone at Karakhadi API-III

The successful passage of the Anvisa GMP inspection at the Karakhadi API-III facility underscores the company's adherence to international manufacturing and quality standards. Anvisa, as Brazil's primary health regulatory authority, conducts rigorous GMP inspections to ensure that pharmaceutical manufacturing sites comply with global quality benchmarks before their products can be approved for the Brazilian market.

The following key details summarize the inspection outcome:

Significance of the Anvisa Clearance

Passing an Anvisa GMP inspection is a critical step for pharmaceutical manufacturers seeking to supply active pharmaceutical ingredients to the Brazilian market, one of the largest pharmaceutical markets in Latin America. A clean inspection outcome — with no observations or deficiencies noted — reflects positively on the quality systems and manufacturing practices maintained at the Karakhadi API-III site.

Alembic Pharmaceuticals' ability to clear this inspection for multiple APIs simultaneously further highlights the operational readiness and compliance posture of the facility. This clearance is expected to support the company's regulatory standing with Anvisa and its broader presence in regulated international markets.